SecBot SecBot
SECBOTREPLAY Home › Report › PLRX

PLRX · Pliant Therapeutics announced FDA Fast Track designation for…

Pliant Therapeutics, Inc. · PRESS-RELEASE filed Aug 18, 2026 at 08:30 ET

At the news

BULLISHIMPACT 4/10

PRESS-RELEASE filed Aug 18, 2026 at 08:30 ET

Pliant Therapeutics announced FDA Fast Track designation for PLN-101095, an oral dual integrin inhibitor for ICI-refractory solid tumors. The designation provides regulatory benefits (rolling NDA, priority review eligibility) but is a procedural milestone, not a clinical data readout.

  • FDA Fast Track designation granted for PLN-101095 in combination with pembrolizumab for ICI-refractory solid tumors
  • PLN-101095 is an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins
  • Currently being evaluated in Phase 1a/1b FORTIFY trial (NCT06270706) with data expected in 2027
  • Fast Track benefits include frequent FDA meetings, rolling NDA submission, and priority review eligibility

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access